Federated Hermes’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$197M Buy
254,946
+8,327
+3% +$6.38M 0.32% 72
2025
Q4
$190M Buy
246,619
+10,419
+4% +$7.08M 0.32% 81
2025
Q3
$133M Sell
236,200
-9,387
-4% -$5.31M 0.23% 103
2025
Q2
$129M Buy
245,587
+204,045
+491% +$114M 0.24% 109
2025
Q1
$26.3M Buy
41,542
+5,579
+16% +$3.84M 0.06% 349
2024
Q4
$25.6M Buy
35,963
+30,304
+536% +$25.4M 0.06% 361
2024
Q3
$5.95M Buy
5,659
+1,875
+50% +$2.09M 0.01% 684
2024
Q2
$3.98M Sell
3,784
-6,391
-63% -$6.2M 0.01% 770
2024
Q1
$9.79M Buy
10,175
+6,961
+217% +$6.62M 0.02% 574
2023
Q4
$2.82M Buy
3,214
+418
+15% +$344K 0.01% 859
2023
Q3
$2.3M Buy
2,796
+160
+6% +$126K 0.01% 877
2023
Q2
$1.89M Buy
2,636
+335
+15% +$258K ﹤0.01% 972
2023
Q1
$1.89M Sell
2,301
-136
-6% -$103K ﹤0.01% 976
2022
Q4
$1.76M Sell
2,437
-2,605
-52% -$1.92M ﹤0.01% 954
2022
Q3
$3.47M Buy
5,042
+371
+8% +$234K 0.01% 753
2022
Q2
$2.76M Buy
4,671
+1,071
+30% +$696K 0.01% 848
2022
Q1
$2.51M Sell
3,600
-55
-2% -$34.8K 0.01% 975
2021
Q4
$2.31M Buy
3,655
+230
+7% +$141K ﹤0.01% 1006
2021
Q3
$2.07M Sell
3,425
-242
-7% -$150K ﹤0.01% 1035
2021
Q2
$2.05M Buy
3,667
+141
+4% +$71.4K ﹤0.01% 1091
2021
Q1
$1.67M Sell
3,526
-922
-21% -$449K ﹤0.01% 1174
2020
Q4
$2.15M Buy
4,448
+572
+15% +$309K ﹤0.01% 1038
2020
Q3
$2.17M Buy
3,876
+167
+5% +$101K 0.01% 956
2020
Q2
$2.31M Sell
3,709
-191,254
-98% -$109M 0.01% 947
2020
Q1
$95.2M Buy
194,963
+156,470
+406% +$64.5M 0.28% 76
2019
Q4
$14.5M Buy
38,493
+25,232
+190% +$8.49M 0.03% 511
2019
Q3
$3.68M Sell
13,261
-1,858
-12% -$550K 0.01% 854
2019
Q2
$4.73M Sell
15,119
-16,889
-53% -$5.62M 0.01% 800
2019
Q1
$13.1M Buy
32,008
+12,477
+64% +$5.14M 0.03% 466
2018
Q4
$7.29M Buy
19,531
+17,234
+750% +$6.31M 0.02% 620
2018
Q3
$928K Sell
2,297
-221
-9% -$84.1K ﹤0.01% 1372
2018
Q2
$868K Sell
2,518
-938
-27% -$293K ﹤0.01% 1330
2018
Q1
$1.19M Buy
3,456
+334
+11% +$116K ﹤0.01% 1167
2017
Q4
$1.17M Sell
3,122
-196
-6% -$79.4K ﹤0.01% 1163
2017
Q3
$1.48M Sell
3,318
-800
-19% -$381K ﹤0.01% 1056
2017
Q2
$2.02M Sell
4,118
-238
-5% -$104K 0.01% 912
2017
Q1
$1.69M Sell
4,356
-150,015
-97% -$55.6M ﹤0.01% 979
2016
Q4
$56.7M Buy
154,371
+151,187
+4,748% +$57.5M 0.17% 118
2016
Q3
$1.28M Buy
3,184
+79
+3% +$31.7K ﹤0.01% 1027
2016
Q2
$1.08M Sell
3,105
-35
-1% -$13.5K ﹤0.01% 1075
2016
Q1
$1.13M Sell
3,140
-2,408
-43% -$992K ﹤0.01% 1046
2015
Q4
$3.01M Sell
5,548
-604
-10% -$327K 0.01% 719
2015
Q3
$2.86M Sell
6,152
-3,069
-33% -$1.65M 0.01% 729
2015
Q2
$4.7M Buy
9,221
+1,365
+17% +$666K 0.01% 626
2015
Q1
$3.55M Sell
7,856
-4,854
-38% -$2.06M 0.01% 728
2014
Q4
$5.21M Sell
12,710
-108,563
-90% -$42.7M 0.02% 598
2014
Q3
$43.7M Sell
121,273
-134
-0.1% -$44.9K 0.14% 140
2014
Q2
$34.3M Buy
121,407
+19,235
+19% +$5.7M 0.11% 190
2014
Q1
$30.7M Buy
102,172
+10,960
+12% +$3.38M 0.1% 194
2013
Q4
$25.1M Buy
91,212
+17,170
+23% +$4.94M 0.09% 216
2013
Q3
$23.2M Buy
74,042
+11,140
+18% +$2.93M 0.09% 185
2013
Q2
$14.1M Buy
+62,902
New +$14.6M 0.06% 266

Other funds holding REGN

Federated Hermes's REGN Position: Q1 2026 in Review

Federated Hermes increased its Regeneron Pharmaceuticals (REGN) stake by 3.4% in Q1 2026, buying an estimated $6.38M and bringing the position to 254,946 shares worth $197M. The position accounts for 0.32% of the portfolio, ranked #72.

Federated Hermes first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Federated Hermes held 254,946 shares of Regeneron Pharmaceuticals worth $197M as of Q1 2026.
  • Federated Hermes bought 8,327 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $6.38M.
  • Regeneron Pharmaceuticals made up 0.32% of Federated Hermes's portfolio in Q1 2026, its #72 holding.
  • Federated Hermes first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.